Find out about the latest clinical trials for cancer patients, including novel immunotherapy approaches.
FEBRUARY 2017
Providence Cancer Center is currently conducting more than 160 research studies, including trials of novel immunotherapy approaches. Please see the links below for a list of studies in specific disease areas.
Highlight: Immunotherapy for breast cancer
David Page, M.D.
Medical oncologist David Page, M.D., is opening an immunotherapy trial of preoperative IRX-2 for patients with early-stage breast cancer:
IRX-2 has been shown to shrink tumors in other kinds of cancer. In this study, Dr. Page will evaluate whether IRX-2 can be given to breast cancer patients while they await lumpectomy/mastectomy, and whether the treatment can stimulate the immune system to attack the breast cancer.
Dr. Page also is leading an immunotherapy study for patients with metastatic triple-negative breast cancer. This study is enrolling patients now:
Immunotherapy is a treatment approach that harnesses the immune system to recognize, attack and eliminate cancer. Providence Cancer Center has conducted research
for more than two decades, beginning long before it was a widely accepted cancer treatment. It was the opportunity to join the Providence team and to conduct immunotherapy research for breast cancer patients that drew Dr. Page to Providence from Memorial Sloan Kettering.
